{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:50:30Z","timestamp":1793332230523,"version":"4.5.0"},"reference-count":208,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12035-024-04260-y","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T02:02:20Z","timestamp":1717984940000},"page":"386-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Novel Gene Therapy Approaches for Targeting Neurodegenerative Disorders: Focusing on Delivering Neurotrophic Genes"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4069-7872","authenticated-orcid":false,"given":"Shobha","family":"Kumari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7975-7991","authenticated-orcid":false,"given":"Aayush","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7861-4860","authenticated-orcid":false,"given":"Sanika Sanjay","family":"Karnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4604-6990","authenticated-orcid":false,"given":"Sumedha","family":"Rohilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7554-3232","authenticated-orcid":false,"given":"Sunil Kumar","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-2990","authenticated-orcid":false,"given":"Rajeev","family":"Taliyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"4260_CR1","first-page":"1","volume":"9","author":"BN Dugger","year":"2016","unstructured":"Dugger BN, Dickson DW (2016) cshperspect-PRI-a028035.pdf. Cold Spring harb Persepect biol 9:1\u201322","journal-title":"Cold Spring harb Persepect biol"},{"key":"4260_CR2","doi-asserted-by":"publisher","unstructured":"Lamptey RNL, Chaulagain B, Trivedi R et al (2022) A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms23031851","DOI":"10.3390\/ijms23031851"},{"key":"4260_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11011-021-00800-w","volume":"37","author":"N Pathak","year":"2022","unstructured":"Pathak N, Vimal SK, Tandon I et al (2022) Neurodegenerative disorders of Alzheimer, parkinsonism, amyotrophic lateral sclerosis and multiple sclerosis: an early diagnostic approach for precision treatment. Metab Brain Dis 37:67\u2013104. https:\/\/doi.org\/10.1007\/s11011-021-00800-w","journal-title":"Metab Brain Dis"},{"key":"4260_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","volume":"16","author":"V Sudhakar","year":"2019","unstructured":"Sudhakar V, Richardson RM (2019) Gene therapy for neurodegenerative diseases. Neurotherapeutics 16:166\u2013175. https:\/\/doi.org\/10.1007\/s13311-018-00694-0","journal-title":"Neurotherapeutics"},{"key":"4260_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jama.285.5.545","volume":"285","author":"EH Kaji","year":"2001","unstructured":"Kaji EH, Leiden JM (2001) Gene and stem cell therapies. JAMA 285:545\u2013550. https:\/\/doi.org\/10.1001\/jama.285.5.545","journal-title":"JAMA"},{"key":"4260_CR6","doi-asserted-by":"publisher","unstructured":"Shahryari A, Jazi MS, Mohammadi S et al (2019) Development and clinical translation of approved gene therapy products for genetic disorders. Front Genet 10. https:\/\/doi.org\/10.3389\/fgene.2019.00868","DOI":"10.3389\/fgene.2019.00868"},{"key":"4260_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ng1092-93","volume":"2","author":"T Friedmann","year":"1992","unstructured":"Friedmann T (1992) A brief history of gene therapy. Nat Genet 2:93\u201398. https:\/\/doi.org\/10.1038\/ng1092-93","journal-title":"Nat Genet"},{"key":"4260_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd2855","volume":"8","author":"E Kennington","year":"2009","unstructured":"Kennington E (2009) Gene therapy delivers an alternative approach to Alzheimer\u2019s disease. Nat Rev Drug Discov 8:275. https:\/\/doi.org\/10.1038\/nrd2855","journal-title":"Nat Rev Drug Discov"},{"key":"4260_CR9","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1089\/hum.2017.160","volume":"28","author":"F Piguet","year":"2017","unstructured":"Piguet F, Alves S, Cartier N (2017) Clinical gene therapy for neurodegenerative diseases: past, present, and future. Hum Gene Ther 28:988\u20131003. https:\/\/doi.org\/10.1089\/hum.2017.160","journal-title":"Hum Gene Ther"},{"key":"4260_CR10","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","volume":"10","author":"W Chen","year":"2020","unstructured":"Chen W, Hu Y, Ju D (2020) Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharm Sin B 10:1347\u20131359. https:\/\/doi.org\/10.1016\/j.apsb.2020.01.015","journal-title":"Acta Pharm Sin B"},{"key":"4260_CR11","doi-asserted-by":"publisher","unstructured":"Quach TT, Stratton HJ, Khanna R et al (2022) Neurodegenerative diseases: from dysproteostasis, altered calcium signalosome to selective neuronal vulnerability to AAV-mediated gene therapy. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms232214188","DOI":"10.3390\/ijms232214188"},{"key":"4260_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/SCS.0b013e318241dc11","volume":"23","author":"EL Scheller","year":"2012","unstructured":"Scheller EL, Villa-Diaz LG, Krebsbach PH (2012) Gene therapy: implications for craniofacial regeneration. J Craniofac Surg 23:333\u2013337. https:\/\/doi.org\/10.1097\/SCS.0b013e318241dc11","journal-title":"J Craniofac Surg"},{"key":"4260_CR13","doi-asserted-by":"publisher","unstructured":"Colucci-D\u2019Amato L, Speranza L, Volpicelli F (2020) Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21207777","DOI":"10.3390\/ijms21207777"},{"key":"4260_CR14","doi-asserted-by":"publisher","unstructured":"Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787\u2013795.\nhttps:\/\/doi.org\/10.1038\/nature05292","DOI":"10.1038\/nature05292"},{"key":"4260_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1515\/revneuro-2016-0035","volume":"30","author":"J Gandhi","year":"2019","unstructured":"Gandhi J, Antonelli AC, Afridi A et al (2019) Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics. Rev Neurosci 30:339\u2013358. https:\/\/doi.org\/10.1515\/revneuro-2016-0035","journal-title":"Rev Neurosci"},{"key":"4260_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3969\/j.issn.1673-5374.2012.05.009","volume":"7","author":"X Chen","year":"2012","unstructured":"Chen X, Guo C, Kong J (2012) Oxidative stress in neurodegenerative diseases. Neural Regen Res 7:376\u2013385. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2012.05.009","journal-title":"Neural Regen Res"},{"key":"4260_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.tips.2008.09.001","volume":"29","author":"D Pratic\u00f2","year":"2008","unstructured":"Pratic\u00f2 D (2008) Oxidative stress hypothesis in Alzheimer\u2019s disease: a reappraisal. Trends Pharmacol Sci 29:609\u2013615. https:\/\/doi.org\/10.1016\/j.tips.2008.09.001","journal-title":"Trends Pharmacol Sci"},{"key":"4260_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00005072-199805000-00005","volume":"57","author":"KS Montine","year":"1998","unstructured":"Montine KS, Reich E, Neely MD et al (1998) Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J Neuropathol Exp Neurol 57:415\u2013425. https:\/\/doi.org\/10.1097\/00005072-199805000-00005","journal-title":"J Neuropathol Exp Neurol"},{"key":"4260_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/s0006-8993(01)02872-4","volume":"920","author":"A Wong","year":"2001","unstructured":"Wong A, L\u00fcth HJ, Deuther-Conrad W et al (2001) Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer\u2019s disease. Brain Res 920:32\u201340. https:\/\/doi.org\/10.1016\/s0006-8993(01)02872-4","journal-title":"Brain Res"},{"key":"4260_CR20","doi-asserted-by":"publisher","first-page":"572634","DOI":"10.1155\/2011\/572634","volume":"2011","author":"V Shukla","year":"2011","unstructured":"Shukla V, Mishra SK, Pant HC (2011) Oxidative stress in neurodegeneration. Adv Pharmacol Sci 2011:572634. https:\/\/doi.org\/10.1155\/2011\/572634","journal-title":"Adv Pharmacol Sci"},{"key":"4260_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fnana.2015.00091","volume":"9","author":"J Blesa","year":"2015","unstructured":"Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson\u2019s disease. Front Neuroanat 9:91. https:\/\/doi.org\/10.3389\/fnana.2015.00091","journal-title":"Front Neuroanat"},{"key":"4260_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mrgentox.2008.09.013","volume":"674","author":"L Migliore","year":"2009","unstructured":"Migliore L, Copped\u00e8 F (2009) Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mutat Res 674:73\u201384. https:\/\/doi.org\/10.1016\/j.mrgentox.2008.09.013","journal-title":"Mutat Res"},{"key":"4260_CR23","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1289\/ehp.7567","volume":"113","author":"RC Brown","year":"2005","unstructured":"Brown RC, Lockwood AH, Sonawane BR (2005) Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect 113:1250\u20131256. https:\/\/doi.org\/10.1289\/ehp.7567","journal-title":"Environ Health Perspect"},{"key":"4260_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/toxsci\/kfr239","volume":"124","author":"JR Cannon","year":"2011","unstructured":"Cannon JR, Greenamyre JT (2011) The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci 124:225\u2013250. https:\/\/doi.org\/10.1093\/toxsci\/kfr239","journal-title":"Toxicol Sci"},{"key":"4260_CR25","doi-asserted-by":"publisher","unstructured":"Ghemrawi R, Khair M (2020) Endoplasmic reticulum stress and unfolded protein response in neurodegenerative diseases. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21176127","DOI":"10.3390\/ijms21176127"},{"key":"4260_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1146\/annurev.biochem.74.050304.091637","volume":"74","author":"IM Verma","year":"2005","unstructured":"Verma IM, Weitzman MD (2005) Gene therapy: twenty-first century medicine. Annu Rev Biochem 74:711\u2013738. https:\/\/doi.org\/10.1146\/annurev.biochem.74.050304.091637","journal-title":"Annu Rev Biochem"},{"key":"4260_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/2277-9175.98152","volume":"1","author":"N Nayerossadat","year":"2012","unstructured":"Nayerossadat N, Ali P, Maedeh T (2012) Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 1:27. https:\/\/doi.org\/10.4103\/2277-9175.98152","journal-title":"Adv Biomed Res"},{"key":"4260_CR28","volume-title":"Cell and gene therapy, twenty fou","author":"K Skorecki","year":"2012","unstructured":"Skorecki K, Galun E (2012) Cell and gene therapy, twenty fou. Elsevier Inc"},{"key":"4260_CR29","volume-title":"Gene therapy, second edi","author":"AM Hedgecoe","year":"2012","unstructured":"Hedgecoe AM (2012) Gene therapy, second edi. Elsevier Inc"},{"key":"4260_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0473-8","author":"DP Wolf","year":"2019","unstructured":"Wolf DP, Mitalipov PA, Mitalipov SM (2019) Principles of and strategies for germline gene therapy. Nat Med. https:\/\/doi.org\/10.1038\/s41591-019-0473-8. 25:","journal-title":"Nat Med"},{"key":"4260_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/b0-08-043076-7\/03364-7","volume":"7","author":"MR Moon","year":"1997","unstructured":"Moon MR, Friedman Ross L (1997) Ethical issues in the new genetics. FORUM - Trends Exp Clin Med 7:295\u2013304. https:\/\/doi.org\/10.1016\/b0-08-043076-7\/03364-7","journal-title":"FORUM - Trends Exp Clin Med"},{"key":"4260_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/1566523217666171013124150","volume":"17","author":"A Donde","year":"2017","unstructured":"Donde A, Wong PC, Chen LL (2017) Challenges and advances in gene therapy approaches for neurodegenerative disorders. Curr Gene Ther 17:187\u2013193. https:\/\/doi.org\/10.2174\/1566523217666171013124150","journal-title":"Curr Gene Ther"},{"key":"4260_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-94-017-9214-1_9","volume":"6","author":"K Grosios","year":"2015","unstructured":"Grosios K, Petry H, Lubelski J (2015) Adeno-associated virus gene therapy and its application to the prevention and personalised treatment of rare diseases. Adv Predict Prev Pers Med 6:131\u2013157. https:\/\/doi.org\/10.1007\/978-94-017-9214-1_9","journal-title":"Adv Predict Prev Pers Med"},{"key":"4260_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgeed.2022.903139","volume":"4","author":"A Sivakumar","year":"2022","unstructured":"Sivakumar A, Cherqui S (2022) Advantages and limitations of gene therapy and gene editing for Friedreich\u2019s ataxia. Front Genome Ed 4:1\u201311. https:\/\/doi.org\/10.3389\/fgeed.2022.903139","journal-title":"Front Genome Ed"},{"key":"4260_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/sj.bjc.6606031","volume":"104","author":"M Vitucci","year":"2011","unstructured":"Vitucci M, Hayes DN, Miller CR (2011) Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer 104:545\u2013553. https:\/\/doi.org\/10.1038\/sj.bjc.6606031","journal-title":"Br J Cancer"},{"key":"4260_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1748-720X.1992.tb01171.x","volume":"20","author":"JC Fletcher","year":"1992","unstructured":"Fletcher JC, Anderson WF (1992) Germ-line gene therapy: a new stage of debate. J Law Med Ethics 20:26\u201339. https:\/\/doi.org\/10.1111\/j.1748-720X.1992.tb01171.x","journal-title":"J Law Med Ethics"},{"key":"4260_CR37","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/mds.27993","volume":"35","author":"JG Nutt","year":"2020","unstructured":"Nutt JG, Curtze C, Hiller A et al (2020) Aromatic L-amino acid decarboxylase gene therapy enhances Levodopa response in Parkinson\u2019s disease. Mov Disord 35:851\u2013858. https:\/\/doi.org\/10.1002\/mds.27993","journal-title":"Mov Disord"},{"key":"4260_CR38","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ymthe.2017.03.027","volume":"25","author":"S Yl\u00e4-Herttuala","year":"2017","unstructured":"Yl\u00e4-Herttuala S, Baker AH (2017) Cardiovascular gene therapy: past, present, and future. Mol Ther 25:1095\u20131106. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.027","journal-title":"Mol Ther"},{"key":"4260_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/gt.2009.4","volume":"16","author":"M Hedman","year":"2009","unstructured":"Hedman M, Muona K, Hedman A et al (2009) Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther 16:629\u2013634. https:\/\/doi.org\/10.1038\/gt.2009.4","journal-title":"Gene Ther"},{"key":"4260_CR40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1089\/hum.2019.367","volume":"31","author":"MJ Castle","year":"2020","unstructured":"Castle MJ, Baltan\u00e1s FC, Kovacs I et al (2020) Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for alzheimer\u2019s disease identifies a need for improved vector delivery. Hum Gene Ther 31:415\u2013422. https:\/\/doi.org\/10.1089\/hum.2019.367","journal-title":"Hum Gene Ther"},{"key":"4260_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00487-6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H et al (2021) Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-021-00487-6. 6:","journal-title":"Signal Transduct Target Ther"},{"key":"4260_CR42","volume-title":"Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases","author":"DGT Parambi","year":"2022","unstructured":"Parambi DGT, Alharbi KS, Kumar R et al (2022) Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases. Springer US"},{"key":"4260_CR43","first-page":"110","volume":"11","author":"R Gardl\u00edk","year":"2005","unstructured":"Gardl\u00edk R, P\u00e1lffy R, Hodosy J et al (2005) Vectors and delivery systems in gene therapy. Med Sci Monit 11:110\u2013121","journal-title":"Med Sci Monit"},{"key":"4260_CR44","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2217\/fmb.10.100","volume":"5","author":"P Maier","year":"2010","unstructured":"Maier P, Von Kalle C, Laufs S (2010) Retroviral vectors for gene therapy. Future Microbiol 5:1507\u20131523. https:\/\/doi.org\/10.2217\/fmb.10.100","journal-title":"Future Microbiol"},{"key":"4260_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.omtm.2017.10.001","volume":"8","author":"V Poletti","year":"2018","unstructured":"Poletti V, Mavilio F (2018) Interactions between retroviruses and the host cell genome. Mol Ther Methods Clin Dev 8:31\u201341. https:\/\/doi.org\/10.1016\/j.omtm.2017.10.001","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4260_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12033-007-0021-5","volume":"36","author":"JT Douglas","year":"2007","unstructured":"Douglas JT (2007) Adenoviral vectors for gene therapy. Mol Biotechnol 36:71\u201380. https:\/\/doi.org\/10.1007\/s12033-007-0021-5","journal-title":"Mol Biotechnol"},{"key":"4260_CR47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nrg1066","volume":"4","author":"CE Thomas","year":"2003","unstructured":"Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:346\u2013358. https:\/\/doi.org\/10.1038\/nrg1066","journal-title":"Nat Rev Genet"},{"key":"4260_CR48","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1002\/cpmo.58","volume":"8","author":"YH Chen","year":"2018","unstructured":"Chen YH, Keiser MS, Davidson BL (2018) Viral vectors for gene transfer. Curr Protoc Mouse Biol 8:e58. https:\/\/doi.org\/10.1002\/cpmo.58","journal-title":"Curr Protoc Mouse Biol"},{"key":"4260_CR49","doi-asserted-by":"publisher","unstructured":"Cearley CN, Vandenberghe LH, Parente MK et al (2011) Cearley 2008 ICV AAV serotypes patterns of transduciton after neonatal admin.pdf. 16:1710\u20131718. https:\/\/doi.org\/10.1038\/mt.2008.166.Expanded","DOI":"10.1038\/mt.2008.166.Expanded"},{"key":"4260_CR50","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U (2018) Clinical use of lentiviral vectors. Leukemia 32:1529\u20131541. https:\/\/doi.org\/10.1038\/s41375-018-0106-0","journal-title":"Leukemia"},{"key":"4260_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/diseases6020042","volume":"103","author":"N Slade","year":"2001","unstructured":"Slade N (2001) Viral vectors in gene therapy. Period Biol 103:139\u2013143. https:\/\/doi.org\/10.3390\/diseases6020042","journal-title":"Period Biol"},{"key":"4260_CR52","doi-asserted-by":"publisher","first-page":"1233151","DOI":"10.1126\/science.1233151","volume":"341","author":"A Aiuti","year":"2013","unstructured":"Aiuti A, Biasco L, Scaramuzza S et al (2013) Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341:1233151. https:\/\/doi.org\/10.1126\/science.1233151","journal-title":"Science"},{"key":"4260_CR53","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","volume":"72","author":"T Dull","year":"1998","unstructured":"Dull T, Zufferey R, Kelly M et al (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463\u20138471. https:\/\/doi.org\/10.1128\/JVI.72.11.8463-8471.1998","journal-title":"J Virol"},{"key":"4260_CR54","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nbt1216","volume":"24","author":"E Montini","year":"2006","unstructured":"Montini E, Cesana D, Schmidt M et al (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24:687\u2013696. https:\/\/doi.org\/10.1038\/nbt1216","journal-title":"Nat Biotechnol"},{"key":"4260_CR55","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","volume":"4","author":"F Mingozzi","year":"2017","unstructured":"Mingozzi F, High KA (2017) Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape. Annu Rev Virol 4:511\u2013534. https:\/\/doi.org\/10.1146\/annurev-virology-101416-041936","journal-title":"Annu Rev Virol"},{"key":"4260_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","volume":"58","author":"D Escors","year":"2010","unstructured":"Escors D, Breckpot K (2010) Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) 58:107\u2013119. https:\/\/doi.org\/10.1007\/s00005-010-0063-4","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"4260_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1119(01)00322-5","volume":"264","author":"DS Latchman","year":"2001","unstructured":"Latchman DS (2001) Gene delivery and gene therapy with herpes simplex virus-based vectors. Gene 264:1\u20139. https:\/\/doi.org\/10.1016\/S0378-1119(01)00322-5","journal-title":"Gene"},{"key":"4260_CR58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.phrs.2009.10.002","volume":"61","author":"ST Lim","year":"2010","unstructured":"Lim ST, Airavaara M, Harvey BK (2010) Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 61:14\u201326. https:\/\/doi.org\/10.1016\/j.phrs.2009.10.002","journal-title":"Pharmacol Res"},{"key":"4260_CR59","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/978-1-4419-1132-2_10","volume":"655","author":"P Marconi","year":"2009","unstructured":"Marconi P, Argnani R, Epstein AL, Manservigi R (2009) HSV as a vector in vaccine development and gene therapy. Adv Exp Med Biol 655:118\u2013144. https:\/\/doi.org\/10.1007\/978-1-4419-1132-2_10","journal-title":"Adv Exp Med Biol"},{"key":"4260_CR60","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.neuron.2016.09.021","volume":"92","author":"DGR Tervo","year":"2016","unstructured":"Tervo DGR, Hwang B-Y, Viswanathan S et al (2016) A designer AAV variant permits efficient retrograde access to projection neurons. Neuron 92:372\u2013382. https:\/\/doi.org\/10.1016\/j.neuron.2016.09.021","journal-title":"Neuron"},{"key":"4260_CR61","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/sj.neo.7900056","volume":"1","author":"A Jacobs","year":"1999","unstructured":"Jacobs A, Breakefield XO, Fraefel C (1999) HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia 1:402\u2013416. https:\/\/doi.org\/10.1038\/sj.neo.7900056","journal-title":"Neoplasia"},{"key":"4260_CR62","doi-asserted-by":"publisher","unstructured":"Gupta PR, Huckfeldt RM (2017) Gene therapy for inherited retinal degenerations: initial successes and future challenges. J Neural Eng 14:51002. https:\/\/doi.org\/10.1088\/1741-2552\/aa7a27","DOI":"10.1088\/1741-2552\/aa7a27"},{"key":"4260_CR63","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1021\/cr800409e","volume":"109","author":"MA Mintzer","year":"2009","unstructured":"Mintzer MA, Simanek EE (2009) Nonviral vectors for gene delivery. Chem Rev 109:259\u2013302. https:\/\/doi.org\/10.1021\/cr800409e","journal-title":"Chem Rev"},{"key":"4260_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1556-276X-9-252","volume":"9","author":"SM Dizaj","year":"2014","unstructured":"Dizaj SM, Jafari S, Khosroushahi AY (2014) A sight on the current nanoparticle-based gene delivery vectors. Nanoscale Res Lett 9:1\u20139. https:\/\/doi.org\/10.1186\/1556-276X-9-252","journal-title":"Nanoscale Res Lett"},{"key":"4260_CR65","volume-title":"Nanoparticles in gene therapy: principles, prospects, and challenges","author":"C Liu","year":"2011","unstructured":"Liu C, Zhang N (2011) Nanoparticles in gene therapy: principles, prospects, and challenges, 1st edn. Elsevier Inc","edition":"1"},{"key":"4260_CR66","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/gt.2012.6","volume":"19","author":"M Nonnenmacher","year":"2012","unstructured":"Nonnenmacher M, Weber T (2012) Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther 19:649\u2013658. https:\/\/doi.org\/10.1038\/gt.2012.6","journal-title":"Gene Ther"},{"key":"4260_CR67","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple SC, Akinc A, Chen J et al (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28:172\u2013176. https:\/\/doi.org\/10.1038\/nbt.1602","journal-title":"Nat Biotechnol"},{"key":"4260_CR68","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/ijms14011629","volume":"14","author":"SK Nitta","year":"2013","unstructured":"Nitta SK, Numata K (2013) Biopolymer-based nanoparticles for drug\/gene delivery and tissue engineering. Int J Mol Sci 14:1629\u20131654. https:\/\/doi.org\/10.3390\/ijms14011629","journal-title":"Int J Mol Sci"},{"key":"4260_CR69","doi-asserted-by":"publisher","unstructured":"Karimi M, Avci P, Mobasseri R et al (2013) The novel albumin-chitosan core-shell nanoparticles for gene delivery: preparation, optimization and cell uptake investigation. J Nanoparticle Res 15. https:\/\/doi.org\/10.1007\/s11051-013-1651-0","DOI":"10.1007\/s11051-013-1651-0"},{"key":"4260_CR70","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1021\/bc0600968","volume":"17","author":"JJ Green","year":"2006","unstructured":"Green JJ, Shi J, Chiu E et al (2006) Biodegradable polymeric vectors for gene delivery to human endothelial cells. Bioconjug Chem 17:1162\u20131169. https:\/\/doi.org\/10.1021\/bc0600968","journal-title":"Bioconjug Chem"},{"key":"4260_CR71","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/s0168-3659(03)00076-2","volume":"89","author":"K Kunath","year":"2003","unstructured":"Kunath K, von Harpe A, Fischer D et al (2003) Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J Control Release off J Control Release Soc 89:113\u2013125. https:\/\/doi.org\/10.1016\/s0168-3659(03)00076-2","journal-title":"J Control Release off J Control Release Soc"},{"key":"4260_CR72","doi-asserted-by":"publisher","unstructured":"Tarvirdipour S, Huang X, Mihali V et al (2020) Peptide-based nanoassemblies in gene therapy and diagnosis: paving the way for clinical application. Molecules 25. https:\/\/doi.org\/10.3390\/molecules25153482","DOI":"10.3390\/molecules25153482"},{"key":"4260_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/oli.2010.0264","volume":"21","author":"J Zhou","year":"2011","unstructured":"Zhou J, Rossi JJ (2011) Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 21:1\u201310. https:\/\/doi.org\/10.1089\/oli.2010.0264","journal-title":"Oligonucleotides"},{"key":"4260_CR74","volume-title":"Dendrimers in gene delivery","author":"DB Rai","year":"2019","unstructured":"Rai DB, Pooja D, Kulhari H (2019) Dendrimers in gene delivery. Elsevier Inc"},{"key":"4260_CR75","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrd1775","volume":"4","author":"DW Pack","year":"2005","unstructured":"Pack DW, Hoffman AS, Pun S, Stayton PS (2005) Design and development of polymers for gene delivery. Nat Rev Drug Discov 4:581\u2013593. https:\/\/doi.org\/10.1038\/nrd1775","journal-title":"Nat Rev Drug Discov"},{"key":"4260_CR76","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/782041","author":"JM Lee","year":"2013","unstructured":"Lee JM, Yoon TJ, Cho YS (2013) Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int 2013. https:\/\/doi.org\/10.1155\/2013\/782041","journal-title":"Biomed Res Int 2013"},{"key":"4260_CR77","doi-asserted-by":"publisher","unstructured":"Ramos-perez V, Cifuentes A, Coronas N et al (2013) Nanomaterial interfaces in biology: methods and protocols. 1025:261\u2013268. https:\/\/doi.org\/10.1007\/978-1-62703-462-3","DOI":"10.1007\/978-1-62703-462-3"},{"key":"4260_CR78","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1089\/scd.2012.0633","volume":"22","author":"MJ Glat","year":"2013","unstructured":"Glat MJ, Offen D (2013) Cell and gene therapy in Alzheimer\u2019s disease. Stem Cells Dev 22:1490\u20131496. https:\/\/doi.org\/10.1089\/scd.2012.0633","journal-title":"Stem Cells Dev"},{"key":"4260_CR79","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1582-4934.2010.01038.x","volume":"14","author":"P Nilsson","year":"2010","unstructured":"Nilsson P, Iwata N, Muramatsu S, ichi et al (2010) Gene therapy in Alzheimer\u2019s disease - potential for disease modification. J Cell Mol Med 14:741\u2013757. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01038.x","journal-title":"J Cell Mol Med"},{"key":"4260_CR80","unstructured":"Khazaei Z et al (2021) Burden of Alzheimer's disease and other dementias in elderly people in asia: a systematic analysis for the global burden of disease study in 2019. Ann Med Health Sci Res 11.6(2021):1496\u20131505"},{"key":"4260_CR81","doi-asserted-by":"publisher","unstructured":"Twohig D, Nielsen HM (2019) \u03b1-synuclein in the pathophysiology of Alzheimer\u2019s disease. Mol Neurodegener 14:23. https:\/\/doi.org\/10.1186\/s13024-019-0320-x","DOI":"10.1186\/s13024-019-0320-x"},{"key":"4260_CR82","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","volume":"67","author":"A Kumar","year":"2015","unstructured":"Kumar A, Singh A (2015) \u00a0A review on Alzheimer\u2019s disease pathophysiology and its management: an update. Pharmacol Rep 67:195\u2013203. https:\/\/doi.org\/10.1016\/j.pharep.2014.09.004","journal-title":"Pharmacol Rep"},{"key":"4260_CR83","doi-asserted-by":"publisher","unstructured":"Fan L, Mao C, Hu X et al (2020) New insights into the pathogenesis of Alzheimer\u2019s disease. 10:1\u201312. https:\/\/doi.org\/10.3389\/fneur.2019.01312","DOI":"10.3389\/fneur.2019.01312"},{"key":"4260_CR84","doi-asserted-by":"publisher","unstructured":"Tiwari S, Atluri V, Kaushik A et al (2019) Alzheimer\u2019s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 14:5541\u20135554. https:\/\/doi.org\/10.2147\/IJN.S200490","DOI":"10.2147\/IJN.S200490"},{"key":"4260_CR85","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejmech.2018.11.049","volume":"163","author":"P Srivastava","year":"2019","unstructured":"Srivastava P, Tripathi PN, Sharma P et al (2019) Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory. Eur J Med Chem 163:116\u2013135. https:\/\/doi.org\/10.1016\/j.ejmech.2018.11.049","journal-title":"Eur J Med Chem"},{"key":"4260_CR86","doi-asserted-by":"publisher","unstructured":"Thakur AK, Kamboj P, Goswami K, Ahuja K (2018) Pathophysiology and management of alzheimer \u2019 s disease: an overview. 7:226\u2013235. https:\/\/doi.org\/10.15406\/japlr.2018.07.00230","DOI":"10.15406\/japlr.2018.07.00230"},{"key":"4260_CR87","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","volume":"525","author":"T Wirth","year":"2013","unstructured":"Wirth T, Parker N, Yl\u00e4-Herttuala S (2013) History of gene therapy. Gene 525:162\u2013169. https:\/\/doi.org\/10.1016\/j.gene.2013.03.137","journal-title":"Gene"},{"key":"4260_CR88","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.molmed.2015.06.001","volume":"21","author":"DMO Connor","year":"2015","unstructured":"Connor DMO, Boulis NM (2015) Gene therapy for neurodegenerative diseases. Trends Mol Med 21:504\u2013512. https:\/\/doi.org\/10.1016\/j.molmed.2015.06.001","journal-title":"Trends Mol Med"},{"key":"4260_CR89","unstructured":"Holtzman DM, Mobley WC (1994) Neurotrophic factors and neurologic disease. West J Med 161(3):246\u201354"},{"key":"4260_CR90","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.017","author":"S Alves","year":"2016","unstructured":"Alves S, Fol R, Cartier N (2016) Gene therapy strategies for Alzheimer\u2019s disease: an overview gene therapy strategies for Alzheimer\u2019s disease. : Overv. https:\/\/doi.org\/10.1089\/hum.2016.017","journal-title":": Overv"},{"key":"4260_CR91","doi-asserted-by":"publisher","unstructured":"El-Battari A, Rodriguez L, Chahinian H et al (2021) Gene therapy strategy for Alzheimer\u2019s and Parkinson\u2019s diseases aimed at preventing the formation of neurotoxic oligomers in SH-SY5Y cells. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms222111550","DOI":"10.3390\/ijms222111550"},{"key":"4260_CR92","doi-asserted-by":"publisher","unstructured":"Stepanichev M (2020) Gene editing and Alzheimer\u2019s disease: is there light at the end of the tunnel ? 2:. https:\/\/doi.org\/10.3389\/fgeed.2020.00004","DOI":"10.3389\/fgeed.2020.00004"},{"key":"4260_CR93","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jare.2021.07.001","volume":"40","author":"S Bhardwaj","year":"2022","unstructured":"Bhardwaj S, Kumar K, Rachamalla M et al (2022) CRISPR \/ Cas9 gene editing: new hope for Alzheimer\u2019s disease therapeutics. J Adv Res 40:207\u2013221. https:\/\/doi.org\/10.1016\/j.jare.2021.07.001","journal-title":"J Adv Res"},{"key":"4260_CR94","unstructured":"Sarwal A, Bhat M, Khanna G, Sidhu KN, Jhamb P, Singh G (2021) Advancements in Alzheimer\u2019s treatment using gene therapy techniques. J Neurol Neurosci ISSN 12(7:9800):2171\u20136625"},{"key":"4260_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchemneu.2016.11.009","volume":"80","author":"SK Yadav","year":"2017","unstructured":"Yadav SK, Rai SN, Singh SP (2017) Mucuna pruriens reduces inducible nitric oxide synthase expression in parkinsonian mice model. J Chem Neuroanat 80:1\u201310. https:\/\/doi.org\/10.1016\/j.jchemneu.2016.11.009","journal-title":"J Chem Neuroanat"},{"key":"4260_CR96","doi-asserted-by":"publisher","unstructured":"Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. https:\/\/doi.org\/10.1038\/nrdp.2017.13","DOI":"10.1038\/nrdp.2017.13"},{"key":"4260_CR97","doi-asserted-by":"publisher","unstructured":"Article R (2020) Parkinson disease. 27\u201342. https:\/\/doi.org\/10.1111\/ene.14108","DOI":"10.1111\/ene.14108"},{"key":"4260_CR98","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jchemneu.2015.12.002","volume":"71","author":"SN Rai","year":"2016","unstructured":"Rai SN, Yadav SK, Singh D, Singh SP (2016) Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced parkinsonian mouse model. J Chem Neuroanat 71:41\u201349. https:\/\/doi.org\/10.1016\/j.jchemneu.2015.12.002","journal-title":"J Chem Neuroanat"},{"key":"4260_CR99","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s11064-014-1443-7","volume":"39","author":"J Prakash","year":"2014","unstructured":"Prakash J, Chouhan S, Yadav SK et al (2014) Withania somnifera alleviates parkinsonian phenotypes by inhibiting apoptotic pathways in dopaminergic neurons. Neurochem Res 39:2527\u20132536. https:\/\/doi.org\/10.1007\/s11064-014-1443-7","journal-title":"Neurochem Res"},{"key":"4260_CR100","doi-asserted-by":"publisher","unstructured":"Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson\u2019s disease. https:\/\/doi.org\/10.1146\/annurev.neuro.28.061604.135718","DOI":"10.1146\/annurev.neuro.28.061604.135718"},{"key":"4260_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36:1\u201312. https:\/\/doi.org\/10.1016\/j.cger.2019.08.002","journal-title":"Clin Geriatr Med"},{"key":"4260_CR102","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev.neuro.28.061604.135718","volume":"28","author":"DJ Moore","year":"2005","unstructured":"Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson\u2019s disease. Annu Rev Neurosci 28:57\u201387. https:\/\/doi.org\/10.1146\/annurev.neuro.28.061604.135718","journal-title":"Annu Rev Neurosci"},{"key":"4260_CR103","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1474-4422(07)70302-2","volume":"7","author":"J Jankovic","year":"2008","unstructured":"Jankovic J (2008) Parkinson\u2019s disease and movement disorders: moving forward. Lancet Neurol 7:9\u201311. https:\/\/doi.org\/10.1016\/S1474-4422(07)70302-2","journal-title":"Lancet Neurol"},{"key":"4260_CR104","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397:2284\u20132303. https:\/\/doi.org\/10.1016\/S0140-6736(21)00218-X","journal-title":"Lancet"},{"key":"4260_CR105","first-page":"73","volume":"31","author":"PJ Loehrer","year":"1999","unstructured":"Loehrer PJ (1999) Current approaches to the treatment of thymoma. Ann Med 31:73\u201379","journal-title":"Ann Med"},{"key":"4260_CR106","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40005-021-00521-3","volume":"51","author":"R Duwa","year":"2021","unstructured":"Duwa R, Jeong JH, Yook S (2021) Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson\u2019s disease. J Pharm Investig 51:465\u2013481. https:\/\/doi.org\/10.1007\/s40005-021-00521-3","journal-title":"J Pharm Investig"},{"key":"4260_CR107","doi-asserted-by":"publisher","first-page":"104760","DOI":"10.1016\/j.nbd.2020.104760","volume":"137","author":"AD Schwab","year":"2020","unstructured":"Schwab AD, Thurston MJ, Machhi J et al (2020) Immunotherapy for Parkinson\u2019s disease. Neurobiol Dis 137:104760. https:\/\/doi.org\/10.1016\/j.nbd.2020.104760","journal-title":"Neurobiol Dis"},{"key":"4260_CR108","doi-asserted-by":"publisher","unstructured":"Barker RA, Parmar M, Kirkeby A et al (2016) Are stem cell-based therapies for Parkinson\u2019s disease ready for the clinic in 2016 ? 6:57\u201363. https:\/\/doi.org\/10.3233\/JPD-160798","DOI":"10.3233\/JPD-160798"},{"key":"4260_CR109","doi-asserted-by":"publisher","unstructured":"Takahashi J (2020) iPS cell-based therapy for Parkinson\u2019s disease: a Kyoto trial. Regen Ther 3\u20137. https:\/\/doi.org\/10.1016\/j.reth.2020.06.002","DOI":"10.1016\/j.reth.2020.06.002"},{"key":"4260_CR110","doi-asserted-by":"publisher","unstructured":"Feng LR, Maguire-Zeiss KA (2010) Gene therapy in Parkinson\u2019s disease: rationale and current status. CNS Drugs 24:177\u2013192. https:\/\/doi.org\/10.2165\/11533740-000000000-00000","DOI":"10.2165\/11533740-000000000-00000"},{"key":"4260_CR111","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/mt.2010.135","volume":"18","author":"S Muramatsu","year":"2009","unstructured":"Muramatsu S, Fujimoto K, Kato S et al (2009) A phase I study of aromatic l-amino acid decarboxylase gene therapy for Parkinson\u2019s disease. Mol Ther 18:1731\u20131735. https:\/\/doi.org\/10.1038\/mt.2010.135","journal-title":"Mol Ther"},{"key":"4260_CR112","doi-asserted-by":"publisher","unstructured":"Axelsen TM, Woldbye DPD (2018) Gene therapy for Parkinson\u2019s disease, an update. J Parkinsons Dis 8:195\u2013215. https:\/\/doi.org\/10.3233\/JPD-181331","DOI":"10.3233\/JPD-181331"},{"key":"4260_CR113","doi-asserted-by":"publisher","unstructured":"Yong W, Ah E, Young M et al (2006) Vesicular monoamine transporter-2 and aromatic l -amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent l -3, 4-dihydroxyphenylalanine administration. 197:215\u2013224. https:\/\/doi.org\/10.1016\/j.expneurol.2005.09.012","DOI":"10.1016\/j.expneurol.2005.09.012"},{"key":"4260_CR114","doi-asserted-by":"publisher","unstructured":"Eberling JL, Jagust WJ, Christine CW et al (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurol 70:1980\u20131983.https:\/\/doi.org\/10.1212\/01.wnl.0000312381.29287.ff","DOI":"10.1212\/01.wnl.0000312381.29287.ff"},{"key":"4260_CR115","doi-asserted-by":"publisher","unstructured":"Grondin R, Zhang Z, Yi A et al (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125:2191\u20132201. https:\/\/doi.org\/10.1093\/brain\/awf234","DOI":"10.1093\/brain\/awf234"},{"key":"4260_CR116","doi-asserted-by":"publisher","unstructured":"Maswood N, Grondin R, Zhang Z et al (2002) Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol Aging 23:881\u2013889. https:\/\/doi.org\/10.1016\/s0197-4580(02)00022-2","DOI":"10.1016\/s0197-4580(02)00022-2"},{"key":"4260_CR117","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/mt.2008.170","volume":"16","author":"CD Herzog","year":"2008","unstructured":"Herzog CD, Dass B, Gasmi M et al (2008) Transgene expression, bioactivity, and safety of CERE-120 (AAV2-Neurturin) following delivery to the monkey striatum. Mol Ther 16:1737\u20131744. https:\/\/doi.org\/10.1038\/mt.2008.170","journal-title":"Mol Ther"},{"key":"4260_CR118","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/sj.mt.6300010","volume":"15","author":"M Gasmi","year":"2007","unstructured":"Gasmi M, Herzog CD, Brandon EP et al (2007) Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson\u2019s disease. Mol Ther 15:62\u201368. https:\/\/doi.org\/10.1038\/sj.mt.6300010","journal-title":"Mol Ther"},{"key":"4260_CR119","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nbd.2007.04.003","volume":"27","author":"M Gasmi","year":"2007","unstructured":"Gasmi M, Brandon EP, Herzog CD et al (2007) AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson\u2019s disease. Neurobiol Dis 27:67\u201376. https:\/\/doi.org\/10.1016\/j.nbd.2007.04.003","journal-title":"Neurobiol Dis"},{"key":"4260_CR120","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0006-8993(02)02934-7","volume":"947","author":"Y Oiwa","year":"2002","unstructured":"Oiwa Y, Yoshimura R, Nakai K, Itakura T (2002) Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson\u2019s disease. Brain Res 947:271\u2013283. https:\/\/doi.org\/10.1016\/S0006-8993(02)02934-7","journal-title":"Brain Res"},{"key":"4260_CR121","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.21032","volume":"60","author":"JH Kordower","year":"2006","unstructured":"Kordower JH, Herzog CD, Dass B et al (2006) Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60:706\u2013715. https:\/\/doi.org\/10.1002\/ana.21032","journal-title":"Ann Neurol"},{"key":"4260_CR122","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/mds.21503","volume":"22","author":"CD Herzog","year":"2007","unstructured":"Herzog CD, Dass B, Holden JE et al (2007) Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 22:1124\u20131132. https:\/\/doi.org\/10.1002\/mds.21503","journal-title":"Mov Disord"},{"key":"4260_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(09)17514-3","volume-title":"Trophic factors therapy in Parkinson\u2019s disease","author":"S Ramaswamy","year":"2009","unstructured":"Ramaswamy S, Soderstrom KE, Kordower JH (2009) Trophic factors therapy in Parkinson\u2019s disease. Elsevier"},{"key":"4260_CR124","doi-asserted-by":"publisher","first-page":"8818","DOI":"10.1073\/pnas.94.16.8818","volume":"94","author":"A Bilang-Bleuel","year":"1997","unstructured":"Bilang-Bleuel A, Revah F, Colin P et al (1997) Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 94:8818\u20138823. https:\/\/doi.org\/10.1073\/pnas.94.16.8818","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4260_CR125","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/378603a0","volume":"378","author":"R Rye","year":"1995","unstructured":"Rye R (1995) \u00a9 19 9 5 Nature Publishing Group. Nature 378:603\u2013605","journal-title":"Nature"},{"key":"4260_CR126","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0304-3940(99)00463-2","volume":"270","author":"M Mogi","year":"1999","unstructured":"Mogi M, Togari A, Kondo T et al (1999) Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson\u2019s disease. Neurosci Lett 270:45\u201348. https:\/\/doi.org\/10.1016\/S0304-3940(99)00463-2","journal-title":"Neurosci Lett"},{"key":"4260_CR127","doi-asserted-by":"publisher","unstructured":"Villate-Beitia I, Puras G, Zarate J et al (2015) First insights into non-invasive administration routes for non-viral gene therapy. https:\/\/doi.org\/10.5772\/61060. Gene Ther - Princ Challenges","DOI":"10.5772\/61060"},{"key":"4260_CR128","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1080\/17425247.2016.1188802","volume":"13","author":"RD Jayant","year":"2016","unstructured":"Jayant RD, Sosa D, Kaushik A et al (2016) Current status of non-viral gene therapy for CNS disorders. Expert Opin Drug Deliv 13:1433\u20131445. https:\/\/doi.org\/10.1080\/17425247.2016.1188802","journal-title":"Expert Opin Drug Deliv"},{"key":"4260_CR129","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1039\/d1nr06939j","volume":"14","author":"A Tasset","year":"2022","unstructured":"Tasset A, Bellamkonda A, Wang W et al (2022) Overcoming barriers in non-viral gene delivery for neurological applications. Nanoscale 14:3698\u20133719. https:\/\/doi.org\/10.1039\/d1nr06939j","journal-title":"Nanoscale"},{"key":"4260_CR130","doi-asserted-by":"publisher","unstructured":"Zhang Y, Schlachetzki F, Zhang Y-F et al (2004) Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum Gene Ther 15:339\u2013350. https:\/\/doi.org\/10.1089\/104303404322959498","DOI":"10.1089\/104303404322959498"},{"key":"4260_CR131","doi-asserted-by":"publisher","unstructured":"Pardridge WM (2005) Tyrosine hydroxylase replacement in experimental Parkinson\u2019s disease with transvascular gene therapy. NeuroRx 2:129\u2013138.\u00a0https:\/\/doi.org\/10.1602\/neurorx.2.1.129","DOI":"10.1602\/neurorx.2.1.129"},{"key":"4260_CR132","doi-asserted-by":"publisher","unstructured":"Bharali DJ, Klejbor I, Stachowiak EK et al (2005) Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci U S A 102:11539\u201311544. https:\/\/doi.org\/10.1073\/pnas.0504926102","DOI":"10.1073\/pnas.0504926102"},{"key":"4260_CR133","doi-asserted-by":"publisher","unstructured":"Huang R, Ma H, Guo Y et al (2013) Angiopep-conjugated nanoparticles for targeted long-term gene therapy of Parkinson\u2019s disease. 2549\u20132559. https:\/\/doi.org\/10.1007\/s11095-013-1005-8","DOI":"10.1007\/s11095-013-1005-8"},{"key":"4260_CR134","doi-asserted-by":"publisher","unstructured":"Bergen JM, Park I, Horner PJ, Pun SH (2008) Expert review nonviral approaches for neuronal delivery of nucleic acids. 25. https:\/\/doi.org\/10.1007\/s11095-007-9439-5","DOI":"10.1007\/s11095-007-9439-5"},{"key":"4260_CR135","doi-asserted-by":"publisher","unstructured":"Gonzalez-barrios JA, Lindahl M, Bannon MJ et al (2006) Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of Hemiparkinsonian rats. 14:857\u2013865. https:\/\/doi.org\/10.1016\/j.ymthe.2006.09.001","DOI":"10.1016\/j.ymthe.2006.09.001"},{"key":"4260_CR136","doi-asserted-by":"publisher","unstructured":"Razgado-hernandez LF, Espadas-alvarez AJ (2015) The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson\u2019s disease. 1\u201325. https:\/\/doi.org\/10.1371\/journal.pone.0117391","DOI":"10.1371\/journal.pone.0117391"},{"key":"4260_CR137","doi-asserted-by":"publisher","unstructured":"Hernandez-chan NG, Bannon MJ, Orozco-barrios CE et al (2015) Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson\u2019s disease. J Biomed Sci 1\u201314. https:\/\/doi.org\/10.1186\/s12929-015-0166-7","DOI":"10.1186\/s12929-015-0166-7"},{"key":"4260_CR138","doi-asserted-by":"publisher","unstructured":"Yurek DM, Fletcher AM, Smith GM et al (2009) Long-term transgene expression in the central nervous system using DNA nanoparticles. 17:641\u2013650. https:\/\/doi.org\/10.1038\/mt.2009.2","DOI":"10.1038\/mt.2009.2"},{"key":"4260_CR139","doi-asserted-by":"publisher","unstructured":"Madsen DA, Schmidt SI, Blaabjerg M, Meyer M (2021) Interaction between Parkin and \u03b1-Synuclein in PARK2-mediated Parkinson\u2019s disease. Cells 10. https:\/\/doi.org\/10.3390\/cells10020283","DOI":"10.3390\/cells10020283"},{"key":"4260_CR140","doi-asserted-by":"publisher","first-page":"135769","DOI":"10.1016\/j.neulet.2021.135769","volume":"750","author":"V Kakoty","year":"2021","unstructured":"Kakoty V, K C S, Dubey SK et al (2021) Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson disease. Neurosci Lett 750:135769. https:\/\/doi.org\/10.1016\/j.neulet.2021.135769","journal-title":"Neurosci Lett"},{"key":"4260_CR141","doi-asserted-by":"publisher","first-page":"101752","DOI":"10.1016\/j.jchemneu.2020.101752","volume":"104","author":"SN Rai","year":"2020","unstructured":"Rai SN, Singh P (2020) Advancement in the modelling and therapeutics of Parkinson\u2019s disease. J Chem Neuroanat 104:101752. https:\/\/doi.org\/10.1016\/j.jchemneu.2020.101752","journal-title":"J Chem Neuroanat"},{"key":"4260_CR142","doi-asserted-by":"publisher","unstructured":"Bianco C, Lo, Schneider BL, Bauer M et al (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an \u2423 -synuclein rat model of Parkinson. https:\/\/doi.org\/10.1073\/pnas.0405313101. \u2019 s disease","DOI":"10.1073\/pnas.0405313101"},{"key":"4260_CR143","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","volume":"344","author":"LP Rowland","year":"2001","unstructured":"Rowland LP, Shneider NA (2001) Amyotrofik lateral sclerosis. Engl J 344:1688\u20131700","journal-title":"Engl J"},{"key":"4260_CR144","doi-asserted-by":"publisher","unstructured":"Hardiman O, Al-Chalabi A, Chio A et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Prim 3. https:\/\/doi.org\/10.1038\/nrdp.2017.71","DOI":"10.1038\/nrdp.2017.71"},{"key":"4260_CR145","doi-asserted-by":"publisher","first-page":"295","DOI":"10.14336\/AD.2013.0400295","volume":"4","author":"PH Gordon","year":"2013","unstructured":"Gordon PH (2013) Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis 4:295\u2013310. https:\/\/doi.org\/10.14336\/AD.2013.0400295","journal-title":"Aging Dis"},{"key":"4260_CR146","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","volume":"390","author":"MA van Es","year":"2017","unstructured":"van Es MA, Hardiman O, Chio A et al (2017) Amyotrophic lateral sclerosis. Lancet 390:2084\u20132098. https:\/\/doi.org\/10.1016\/S0140-6736(17)31287-4","journal-title":"Lancet"},{"key":"4260_CR147","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1513\/pats.201008-055MS","volume":"8","author":"M Bouchecareilh","year":"2011","unstructured":"Bouchecareilh M, Balch WE (2011) Proteostasis: a new therapeutic paradigm for pulmonary disease. Proc Am Thorac Soc 8:189\u2013195. https:\/\/doi.org\/10.1513\/pats.201008-055MS","journal-title":"Proc Am Thorac Soc"},{"key":"4260_CR148","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/mt.2013.239","volume":"22","author":"P Patel","year":"2014","unstructured":"Patel P, Kriz J, Gravel M et al (2014) Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther 22:498\u2013510. https:\/\/doi.org\/10.1038\/mt.2013.239","journal-title":"Mol Ther"},{"key":"4260_CR149","doi-asserted-by":"publisher","unstructured":"Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC (2017) Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med 7. https:\/\/doi.org\/10.1101\/cshperspect.a024240","DOI":"10.1101\/cshperspect.a024240"},{"key":"4260_CR150","doi-asserted-by":"publisher","unstructured":"Landray MJ, Bax JJ, Alliot L et al (2017) Improving public health by improving clinical trial guidelines and their application. Eur Heart J 38:1632\u20131637. https:\/\/doi.org\/10.1093\/eurheartj\/ehx086","DOI":"10.1093\/eurheartj\/ehx086"},{"key":"4260_CR151","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.tins.2010.08.002","volume":"33","author":"AJ Milnerwood","year":"2010","unstructured":"Milnerwood AJ, Raymond LA (2010) Early synaptic pathophysiology in neurodegeneration: insights from Huntington\u2019s disease. Trends Neurosci 33:513\u2013523. https:\/\/doi.org\/10.1016\/j.tins.2010.08.002","journal-title":"Trends Neurosci"},{"key":"4260_CR152","doi-asserted-by":"publisher","unstructured":"Cha JJ (2007) Transcriptional signatures in Huntington \u2019 s disease. 83:228\u2013248. https:\/\/doi.org\/10.1016\/j.pneurobio.2007.03.004","DOI":"10.1016\/j.pneurobio.2007.03.004"},{"key":"4260_CR153","doi-asserted-by":"publisher","unstructured":"Gauthier LR, Charrin BC, Borrell-Pag\u00e8s M et al (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127\u2013138. https:\/\/doi.org\/10.1016\/j.cell.2004.06.018","DOI":"10.1016\/j.cell.2004.06.018"},{"key":"4260_CR154","doi-asserted-by":"publisher","unstructured":"Venero JL, Kn\u00fcsel B, Beck KD, Hefti F (1994) Expression of neurotrophin and trk receptor genes in adult rats with fimbria transections: effect of intraventricular nerve growth factor and brain-derived neurotrophic factor administration. Neurosci 59:797\u2013815. https:\/\/doi.org\/10.1016\/0306-4522(94)90285-2","DOI":"10.1016\/0306-4522(94)90285-2"},{"key":"4260_CR155","doi-asserted-by":"publisher","unstructured":"Schumacher JM, Short MP, Hyman BT et al (1991) Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neurosci 45:561\u2013570. https:\/\/doi.org\/10.1016\/0306-4522(91)90271-o","DOI":"10.1016\/0306-4522(91)90271-o"},{"key":"4260_CR156","doi-asserted-by":"publisher","unstructured":"Glorioso JC, Cohen JB, Carlisle DL, Friedlander RM (2015) Moving toward a gene therapy for Huntington \u2019 s disease. 22:931\u2013933. https:\/\/doi.org\/10.1038\/gt.2015.102","DOI":"10.1038\/gt.2015.102"},{"key":"4260_CR157","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.neuroscience.2016.02.054","volume":"324","author":"J Jeon","year":"2016","unstructured":"Jeon J, Kim W, Jang J (2016) Gene therapy by proteasome activator\n, pa28 c , improves motor coordination and proteasome function in huntington \u2019 s disease yac128 mice. Neuroscience 324:20\u201328. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.02.054","journal-title":"Neuroscience"},{"key":"4260_CR158","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0161-813X(02)00099-2","volume":"23","author":"DA Di Monte","year":"2002","unstructured":"Di Monte DA, Lavasani M, Manning-Bog AB (2002) Environmental factors in Parkinson\u2019s disease. Neurotoxicology 23:487\u2013502. https:\/\/doi.org\/10.1016\/S0161-813X(02)00099-2","journal-title":"Neurotoxicology"},{"key":"4260_CR159","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ana.10487","volume":"53","author":"TT Warner","year":"2003","unstructured":"Warner TT, Schapira AHV, Tatton et al (2003) Genetic and environmental factors in the cause of Parkinson\u2019s disease. Ann Neurol 53:16\u201325. https:\/\/doi.org\/10.1002\/ana.10487","journal-title":"Ann Neurol"},{"key":"4260_CR160","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5114\/fn.2019.85929","volume":"57","author":"RA Armstrong","year":"2019","unstructured":"Armstrong RA (2019) Risk factors for Alzheimer\u2019s disease. Folia Neuropathol 57:87\u2013105. https:\/\/doi.org\/10.5114\/fn.2019.85929","journal-title":"Folia Neuropathol"},{"key":"4260_CR161","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.arr.2010.08.006","volume":"9","author":"CW Hung","year":"2010","unstructured":"Hung CW, Chen YC, Hsieh WL et al (2010) Ageing and neurodegenerative diseases. Ageing Res Rev 9:S36\u2013S46. https:\/\/doi.org\/10.1016\/j.arr.2010.08.006","journal-title":"Ageing Res Rev"},{"key":"4260_CR162","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00441-018-2817-y.Genetic","volume":"176","author":"LR Teras","year":"2017","unstructured":"Teras LR (2017) \u4e73\u9f20\u5fc3\u808c\u63d0\u53d6 HHS Public Access. Physiol Behav 176:139\u2013148. https:\/\/doi.org\/10.1007\/s00441-018-2817-y.Genetic","journal-title":"Physiol Behav"},{"key":"4260_CR163","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1586\/14737175.7.7.887","volume":"7","author":"R Dosunmu","year":"2007","unstructured":"Dosunmu R, Wu J, Basha MR, Zawia NH (2007) Environmental and dietary risk factors in Alzheimer\u2019s disease. Expert Rev Neurother 7:887\u2013900. https:\/\/doi.org\/10.1586\/14737175.7.7.887","journal-title":"Expert Rev Neurother"},{"key":"4260_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JPD-130230.The","volume":"23","author":"Zhou","year":"2012","unstructured":"Zhou et al (2012) \u57fa\u56e0\u7684\u6539\u53d8NIH Public Access. Bone 23:1\u20137. https:\/\/doi.org\/10.3233\/JPD-130230.The","journal-title":"Bone"},{"key":"4260_CR165","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12264-013-1423-y","volume":"30","author":"Z Chen","year":"2014","unstructured":"Chen Z, Zhong C (2014) Oxidative stress in Alzheimer\u2019s disease. Neurosci Bull 30:271\u2013281. https:\/\/doi.org\/10.1007\/s12264-013-1423-y","journal-title":"Neurosci Bull"},{"key":"4260_CR166","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bioorg.2018.12.017","volume":"85","author":"PN Tripathi","year":"2019","unstructured":"Tripathi PN, Srivastava P, Sharma P et al (2019) Biphenyl-3-oxo-1,2,4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory. Bioorg Chem 85:82\u201396. https:\/\/doi.org\/10.1016\/j.bioorg.2018.12.017","journal-title":"Bioorg Chem"},{"key":"4260_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbadis.2013.10.015.Oxidative","volume":"23","author":"LB Bottaro","year":"2008","unstructured":"Bottaro LB, Madhur (2008) \u57fa\u56e0\u7684\u6539\u53d8NIH Public Access. Bone 23:1\u20137. https:\/\/doi.org\/10.1016\/j.bbadis.2013.10.015.Oxidative","journal-title":"Bone"},{"key":"4260_CR168","doi-asserted-by":"publisher","first-page":"122257","DOI":"10.1016\/j.lfs.2023.122257","volume":"334","author":"EE Alshial","year":"2023","unstructured":"Alshial EE, Abdulghaney MI, Wadan AHS et al (2023) Mitochondrial dysfunction and neurological disorders: a narrative review and treatment overview. Life Sci 334:122257. https:\/\/doi.org\/10.1016\/j.lfs.2023.122257","journal-title":"Life Sci"},{"key":"4260_CR169","volume-title":"Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside","author":"A Mishra","year":"2021","unstructured":"Mishra A, Bandopadhyay R, Singh PK et al (2021) Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside. Springer US"},{"key":"4260_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0197-0186(02)00196-1","volume":"43","author":"BS Shastry","year":"2003","unstructured":"Shastry BS (2003) Neurodegenerative disorders of protein aggregation. Neurochem Int 43:1\u20137. https:\/\/doi.org\/10.1016\/S0197-0186(02)00196-1","journal-title":"Neurochem Int"},{"key":"4260_CR171","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1750-3639.2006.00036.x","volume":"16","author":"A Blesch","year":"2006","unstructured":"Blesch A (2006) Neurotrophic factors in neurodegeneration. Brain Pathol 16:295\u2013303. https:\/\/doi.org\/10.1111\/j.1750-3639.2006.00036.x","journal-title":"Brain Pathol"},{"key":"4260_CR172","doi-asserted-by":"publisher","unstructured":"El Ouaamari Y, Van den Bos J, Willekens B et al (2023) Neurotrophic factors as regenerative therapy for neurodegenerative diseases: current status, challenges and future perspectives. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms24043866","DOI":"10.3390\/ijms24043866"},{"key":"4260_CR173","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2337\/diacare.22.4.585","volume":"22","author":"KM Thrailkill","year":"1999","unstructured":"Thrailkill KM, Quattrin T, Baker L et al (1999) Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type I diabetes. Diabetes Care 22:585\u2013592. https:\/\/doi.org\/10.2337\/diacare.22.4.585","journal-title":"Diabetes Care"},{"key":"4260_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01280-3","author":"WZ Eu","year":"2021","unstructured":"Eu WZ, Chen Y, Chen W et al (2021) The effect of nerve growth factor on supporting spatial memory depends upon hippocampal cholinergic innervation. Transl Psychiatry. https:\/\/doi.org\/10.1038\/s41398-021-01280-3","journal-title":"Transl Psychiatry"},{"key":"4260_CR175","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1007\/s11033-021-06512-9","volume":"48","author":"T Athar","year":"2021","unstructured":"Athar T, Balushi K, Al, Alam S, Cholinesterase C (2021) Recent advances on drug development and emerging therapeutic agents for Alzheimer \u2019 s disease. Mol Biol Rep 48:5629\u20135645. https:\/\/doi.org\/10.1007\/s11033-021-06512-9","journal-title":"Mol Biol Rep"},{"key":"4260_CR176","doi-asserted-by":"publisher","unstructured":"Tuszynski MH (2002) Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol 1:51\u201357. https:\/\/doi.org\/10.1016\/s1474-4422(02)00006-6","DOI":"10.1016\/s1474-4422(02)00006-6"},{"key":"4260_CR177","doi-asserted-by":"publisher","unstructured":"Brera B, De Ceballos ML (2014) Leptin gene therapy attenuates neuronal damages evoked by amyloid- b and rescues memory deficits in APP \/ PS1 mice. 298\u2013308. https:\/\/doi.org\/10.1038\/gt.2013.85","DOI":"10.1038\/gt.2013.85"},{"key":"4260_CR178","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cca.2015.08.009","volume":"450","author":"M Ca","year":"2015","unstructured":"Ca M, Mg C, Lp S et al (2015) Leptin in Alzheimer\u2019s disease. Clin Chim Acta 450:162\u2013168. https:\/\/doi.org\/10.1016\/j.cca.2015.08.009","journal-title":"Clin Chim Acta"},{"key":"4260_CR179","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-020-01646-5","author":"C Braschi","year":"2020","unstructured":"Braschi C, Capsoni S, Narducci R et al (2020) Intranasal delivery of BDNF rescues memory deficits in AD11 mice and reduces brain microgliosis. Aging Clin Exp Res. https:\/\/doi.org\/10.1007\/s40520-020-01646-5","journal-title":"Aging Clin Exp Res"},{"key":"4260_CR180","doi-asserted-by":"publisher","unstructured":"Tsybko AS, Ilchibaeva TV, Popova NK (2017) Role of glial cell line-derived neurotrophic factor in the pathogenesis and treatment of mood disorders. https:\/\/doi.org\/10.1515\/revneuro-2016-0063","DOI":"10.1515\/revneuro-2016-0063"},{"key":"4260_CR181","doi-asserted-by":"publisher","unstructured":"Castro-freire M, Perpi U, Revilla S et al (2014)\u00a0Lenti-GDNF gene therapy protects against Alzheimer\u2019s disease-like neuropathology in 3xTg-AD mice and MC65 cells. 1\u201312. https:\/\/doi.org\/10.1111\/cns.12312","DOI":"10.1111\/cns.12312"},{"key":"4260_CR182","doi-asserted-by":"publisher","unstructured":"Phan P, Saikia BB, Sonnaila S et al (2021) The saga of endocrine FGFs. Cells 10. https:\/\/doi.org\/10.3390\/cells10092418","DOI":"10.3390\/cells10092418"},{"key":"4260_CR183","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s11033-021-06890-0","volume":"49","author":"R Alam","year":"2022","unstructured":"Alam R, Mrad Y, Hammoud H et al (2022) New insights into the role of fibroblast growth factors in Alzheimer\u2019s disease. Mol Biol Rep 49:1413\u20131427. https:\/\/doi.org\/10.1007\/s11033-021-06890-0","journal-title":"Mol Biol Rep"},{"key":"4260_CR184","doi-asserted-by":"publisher","unstructured":"Kakoty V, Chih SKC, Yang H et al (2022) Neuroprotective effect of lentivirus\u2013mediated FGF21 gene delivery in experimental Alzheimer \u2019 s disease is augmented when concerted with rapamycin. Mol Neurobiol 2659\u20132677. https:\/\/doi.org\/10.1007\/s12035-022-02741-6","DOI":"10.1007\/s12035-022-02741-6"},{"key":"4260_CR185","doi-asserted-by":"publisher","first-page":"108335","DOI":"10.1016\/j.neuropharm.2020.108335","volume":"181","author":"Y Chen","year":"2020","unstructured":"Chen Y, Shen J, Qi G et al (2020) Potential therapeutic role of fibroblast growth factor 21 in neurodegeneration: evidence for ameliorating parkinsonism via silent information regulator 2 homolog 1 and implication for gene therapy. Neuropharmacology 181:108335. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108335","journal-title":"Neuropharmacology"},{"key":"4260_CR186","doi-asserted-by":"publisher","unstructured":"Yang X, Ji Y, Wang W, et al (2021) Amyotrophic lateral sclerosis: molecular mechanisms, biomarkers, and therapeutic strategies. Antioxidants (Basel, Switzerland) 10. https:\/\/doi.org\/10.3390\/antiox10071012","DOI":"10.3390\/antiox10071012"},{"key":"4260_CR187","doi-asserted-by":"publisher","unstructured":"Hayes LR, Kalab P (2022) Emerging therapies and novel targets for TDP \u2013 43 proteinopathy in ALS \/ FTD. Neurotherapeutics 1061\u20131084. https:\/\/doi.org\/10.1007\/s13311-022-01260-5","DOI":"10.1007\/s13311-022-01260-5"},{"key":"4260_CR188","doi-asserted-by":"publisher","unstructured":"Delaye JB, Lanznaster D, Veyrat-Durebex C et al (2021) Behavioral, hormonal, inflammatory, and metabolic effects associated with FGF21-pathway activation in an ALS mouse model. Neurother J Am Soc Exp Neurother 18:297\u2013308. https:\/\/doi.org\/10.1007\/s13311-020-00933-3","DOI":"10.1007\/s13311-020-00933-3"},{"key":"4260_CR189","doi-asserted-by":"publisher","unstructured":"Voutilainen MH, Laure J, Pera J et al (2007) Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. 448:73\u201378. https:\/\/doi.org\/10.1038\/nature05957","DOI":"10.1038\/nature05957"},{"key":"4260_CR190","first-page":"173","volume":"20","author":"AN Mesencephalic","year":"2003","unstructured":"Mesencephalic AN, Factor AN, Petrova PS et al (2003) MANF 20:173\u2013187","journal-title":"MANF"},{"key":"4260_CR191","doi-asserted-by":"publisher","unstructured":"Huttunen HJ, Saarma M (2019) CDNF protein therapy in Parkinson\u2019s disease. 28:349\u2013366. https:\/\/doi.org\/10.1177\/0963689719840290","DOI":"10.1177\/0963689719840290"},{"key":"4260_CR192","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/mt.2014.206","volume":"23","author":"\u00d3 Cordero-llana","year":"2015","unstructured":"Cordero-llana \u00d3, Houghton BC, Rinaldi F et al (2015) Enhanced efficacy of the CDNF \/ MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson\u2019s disease. Mol Ther 23:244\u2013254. https:\/\/doi.org\/10.1038\/mt.2014.206","journal-title":"Mol Ther"},{"key":"4260_CR193","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.3233\/jpd-212724","volume":"11","author":"AD Van Laar","year":"2021","unstructured":"Van Laar AD, Van Laar VS, San Sebastian W et al (2021) An update on gene therapy approaches for Parkinson\u2019s disease: restoration of dopaminergic function. J Parkinsons Dis 11:S173\u2013S182. https:\/\/doi.org\/10.3233\/jpd-212724","journal-title":"J Parkinsons Dis"},{"key":"4260_CR194","doi-asserted-by":"publisher","unstructured":"Li Y, Wang J, Zhang S, Liu Z (2015) Neprilysin gene transfer: a promising therapeutic approach for Alzheimer\u2019s disease. 1329:1325\u20131329. https:\/\/doi.org\/10.1002\/jnr.23564","DOI":"10.1002\/jnr.23564"},{"key":"4260_CR195","doi-asserted-by":"publisher","unstructured":"Schindowski K, Belarbi K, Bue L (2008) Neurotrophic factors in Alzheimer\u2019s disease: role of axonal transport. 7:43\u201356. https:\/\/doi.org\/10.1111\/j.1601-183X.2007.00378.x","DOI":"10.1111\/j.1601-183X.2007.00378.x"},{"key":"4260_CR196","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.2353\/ajpath.2008.070620","volume":"172","author":"SS El-amouri","year":"2008","unstructured":"El-amouri SS, Zhu H, Yu J et al (2008) Neprilysin: an enzyme candidate to slow the progression of Alzheimer\u2019s disease. Am J Pathol 172:1342\u20131354. https:\/\/doi.org\/10.2353\/ajpath.2008.070620","journal-title":"Am J Pathol"},{"key":"4260_CR197","doi-asserted-by":"publisher","unstructured":"Hamilton K, Harvey J (2021) The neuronal actions of leptin and the implications for treating Alzheimer\u2019s disease. Pharmaceuticals (Basel) 14. https:\/\/doi.org\/10.3390\/ph14010052","DOI":"10.3390\/ph14010052"},{"key":"4260_CR198","doi-asserted-by":"publisher","unstructured":"Miranda-lourenc C, Ribeiro-rodrigues L (2020) Journal Pre-proof. https:\/\/doi.org\/10.1016\/j.phrs.2020.105281","DOI":"10.1016\/j.phrs.2020.105281"},{"key":"4260_CR199","doi-asserted-by":"publisher","unstructured":"Nagahara AH, Merrill DA, Coppola G et al (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer\u2019s disease. 15:331\u2013337. https:\/\/doi.org\/10.1038\/nm.1912","DOI":"10.1038\/nm.1912"},{"key":"4260_CR200","doi-asserted-by":"publisher","unstructured":"Fang T, Je G, Pacut P et al (2022) Gene therapy in amyotrophic lateral sclerosis. https:\/\/doi.org\/10.3390\/cells11132066. Cells 11:","DOI":"10.3390\/cells11132066"},{"key":"4260_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2202-6-4","volume":"6","author":"TJ Price","year":"2005","unstructured":"Price TJ, Louria MD, Candelario-Soto D et al (2005) Treatment of trigeminal ganglion neurons in vitro with NGF, GDNF or BDNF: effects on neuronal survival, neurochemical properties and TRPV1-mediated neuropeptide secretion. BMC Neurosci 6:1\u201315. https:\/\/doi.org\/10.1186\/1471-2202-6-4","journal-title":"BMC Neurosci"},{"key":"4260_CR202","doi-asserted-by":"publisher","unstructured":"Sun J, Roy S (2021) Gene-based therapies for neurodegenerative diseases. Nat Neurosci 24:297\u2013311. https:\/\/doi.org\/10.1038\/s41593-020-00778-1","DOI":"10.1038\/s41593-020-00778-1"},{"key":"4260_CR203","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-neuro-071013-014300","volume":"37","author":"JT Yu","year":"2014","unstructured":"Yu JT, Tan L, Hardy J (2014) Apolipoprotein e in Alzheimer\u2019s disease: an update. Annu Rev Neurosci 37:79\u2013100. https:\/\/doi.org\/10.1146\/annurev-neuro-071013-014300","journal-title":"Annu Rev Neurosci"},{"key":"4260_CR204","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1089\/humc.2017.231","volume":"29","author":"JB Rosenberg","year":"2018","unstructured":"Rosenberg JB, Kaplitt MG, De BP et al (2018) AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer\u2019s disease. Hum Gene Ther Clin Dev 29:24\u201347. https:\/\/doi.org\/10.1089\/humc.2017.231","journal-title":"Hum Gene Ther Clin Dev"},{"key":"4260_CR205","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-6606-4-3","volume":"4","author":"YW Zhang","year":"2011","unstructured":"Zhang YW, Thompson R, Zhang H, Xu H (2011) APP processing in Alzheimer\u2019s disease. Mol Brain 4:3. https:\/\/doi.org\/10.1186\/1756-6606-4-3","journal-title":"Mol Brain"},{"key":"4260_CR206","doi-asserted-by":"publisher","unstructured":"Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, Dickler M, Mar Robson M, Moy F, Goswami S, Oktay (2016) K.Impairment of BRCA1-related DNA double strand break repair leads to ovarian aging in mice and humans, 2013, Sci Transl Med. 5(172):1\u201325 \u808c\u8089\u4f5c\u4e3a\u5185\u5206\u6ccc\u548c\u65c1\u5206\u6ccc\u5668\u5b98 HHS Public Access. Physiol Behav 176:139\u2013148. https:\/\/doi.org\/10.1126\/scitranslmed.aag0481.Tau","DOI":"10.1126\/scitranslmed.aag0481.Tau"},{"key":"4260_CR207","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","volume":"26","author":"B Kantor","year":"2018","unstructured":"Kantor B, Tagliafierro L, Gu J et al (2018) Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD. Mol Ther 26:2638\u20132649. https:\/\/doi.org\/10.1016\/j.ymthe.2018.08.019","journal-title":"Mol Ther"},{"key":"4260_CR208","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1093\/brain\/awt097","volume":"136","author":"RA Saccon","year":"2013","unstructured":"Saccon RA, Bunton-Stasyshyn RKA, Fisher EMC, Fratta P (2013) Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 136:2342\u20132358. https:\/\/doi.org\/10.1093\/brain\/awt097","journal-title":"Brain"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04260-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-024-04260-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04260-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T16:42:16Z","timestamp":1736354536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-024-04260-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":208,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["4260"],"URL":"https:\/\/doi.org\/10.1007\/s12035-024-04260-y","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}